Changyang Technology: Plans to invest in a colorless and transparent polyimide film project with an annual output of 1 million square meters

Related posts

• Buzzing stocks.Stocks that will see action today: May 14, 2024

  , Alkosign Ltd has received order from Appario Retail Private Ltd for Supply of total 4761 quantity of Whiteboard Dry Magnetic with pen Tray and Aluminum Trim includes 6 Magnets, 1 eraser and 2 dry erase markers in two different sizes for the consideration amount of ₹33,59,610.

  US stock news May 14, 2024

• Markets extend gains for 5th session; Sensex revisits 74k

  Rising for the fifth straight session, equity benchmark Sensex rallied nearly 500 points to reclaim the 74,000 mark while the Nifty closed above the 22,550 level on Thursday, driven by heavy buying in banking, financial and metal stocks.

  US stock news April 26, 2024

• Everest Property & Casualty Insurance’s capital increase of 80 million yuan has been promoted for 9 months but has not yet been implemented. When will the Class C risk rating be removed?

  Log in to Sina Finance APP and search [Xinpi] to view more evaluation grades Source: Blue Whale Finance Since the first quarter of 2022, the comprehensive risk rating of Everest Property Insurance has been downgraded from B to Category C, and the solvency is not up to standard. (Picture source: Visual China) After the announcement of a change in registered capital was disclosed in July 2023, and the registered capital was planned to be changed from 1 billion yuan to 1.08 billion yuan, Everest Property & Casualty Insurance Co., Ltd. (hereinafter referred to as \”Everest Property & Casualty Insurance\”) ) There has been no news of progress on this matter. Nine months later, on April 24, the company disclosed another relevant announcement, but the content was not that the capital increase was approved, but that the board of directors reviewed and approved the \”Proposal on Review of the Supplementary Plan for the \”New Capital Plan\”\” , the original capital increase amount remains unchanged, and some matters are supplemented to promote the implementation of subsequent capital increase matters. At the same…

  US stock news April 25, 2024

• Xiaomo: Changshi Group has strong execution and financial management capabilities. We believe that Phoenix Energy can turn around losses in the medium to long term.

  JPMorgan Chase released a research report stating that Cheung Kong Infrastructure (01038), Cheung Kong Holdings (01113) and Electric Power Industries (00006) jointly announced that they would form a consortium to acquire Phoenix Energy, a gas distribution network in Northern Ireland. Based on the consideration payable of more than 3 billion yuan, its enterprise value (EV) to regulatory asset value (RAV) valuation ratio is about 1 times. Since this is the first large-scale acquisition of the Yangtze River Group in Europe in the past five years, it is expected to eliminate the market Concerns about business being affected by geopolitical tensions. The bank pointed out that Phoenix Energy has more than 250,000 customers. Although the company suffered losses last year, it believes that with the strong execution and financial management capabilities of Yangtze River Group, it can turn losses into profits in the medium to long term. Overall, due to the small scale of this transaction, JPMorgan expects to have little impact on the stock price. It maintains a \”neutral\” rating for Changshi. The stock price is expected to fluctuate within…

  US stock news April 25, 2024

• PVR Inox partners with Devyani International to develop and operate food courts in shopping malls

  PVR Inox has entered into a shareholders’ agreement with Devyani International Ltd to incorporate a new company for developing and operating food courts in shopping malls

  US stock news May 15, 2024

• Chengyi Pharmaceutical: Net profit will increase by 0.81% year-on-year in 2023, with plans to send 2 yuan per 10 pieces

  Chengyi Pharmaceutical (603811) disclosed its 2023 annual report on April 26. In 2023, the company achieved operating income of 672 million yuan, a year-on-year increase of 2.54%; net profit attributable to the parent company was 163 million yuan, a year-on-year increase of 0.81%; non-net profit after deducting 155 million yuan, a year-on-year increase of 10.6%; net cash flow generated from operating activities was 195 million yuan, a year-on-year increase of 17.38%; during the reporting period, Chengyi Pharmaceutical’s basic earnings per share was 0.5 yuan, and the weighted average return on net assets was 14.35%. The company\’s 2023 distribution plan is: It plans to distribute 2 yuan (tax included) to all shareholders for every 10 shares.

  US stock news April 25, 2024